The dawn phenomenon revisited: implications for diabetes therapy.
about
Closed-loop artificial pancreas systems: physiological input to enhance next-generation devices.Oscillations in joint synchrony of reproductive hormones in healthy men.Clinical experience with insulin glargine in type 1 diabetes.Fitting dynamic models with forcing functions: application to continuous glucose monitoring in insulin therapy.Closed-loop insulin delivery in type 1 diabetes.Insulin doses before and one year after pump start: children have a reversed dawn phenomenon.The Effects of Transition from Bedtime to Morning Glargine Administration in Patients with Poorly Regulated Type 1 Diabetes Mellitus: Croatian Pilot Study.Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age.In-Silico Trials for Glucose Control in Hospitalized Patients with Type 2 DiabetesMagnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: Basal dosing.Identification of intraday metabolic profiles during closed-loop glucose control in individuals with type 1 diabetes.Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home.Modeling of 24-hour glucose and insulin profiles of patients with type 2 diabetes.Closed-loop insulin delivery: from bench to clinical practice.Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy.Rebound hyperglycaemia in diabetic cats.Interrelationship between 3,5,3´-triiodothyronine and the circadian clock in the rodent heart.Predicted blood glucose from insulin administration based on values from miscoded glucose meters.Effect of growth hormone on dawn phenomenon in patients with type 2 diabetes.Control of type 1 diabetes mellitus and shift work.Insulin pump therapy: guidelines for successful outcomes.[Post-prandial hyperglycemia in type 2 diabetes patients].Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes.Views and Experiences of New Zealand Women with Gestational Diabetes in Achieving Glycaemic Control Targets: The Views Study.Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes.Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus.
P2860
Q30405467-1D77E36E-1806-4E81-ACAD-A0B798BA042AQ30423552-AB206F8C-2960-4927-AC3D-85616C9CFD7DQ34296834-13D61B5D-7FC8-42D7-9ADC-4D1B6F77F0ABQ35447304-E9770E8C-5B61-4905-B631-DD81262EC595Q35954124-424A0F6D-0745-4C72-905C-D331670EFC56Q36229004-30C099ED-9F4E-46CC-8EA2-8DD1C79143C1Q36360075-FA1D7274-F2B8-4981-9427-8AA828110C38Q36426907-607BBE3C-7997-4AA0-874B-0FB0AB8FA01AQ36509957-57B88BF7-1AFB-4365-8A60-D1E0C1B01F2EQ37331375-B4B47CDE-1F22-471D-AC9F-96C6B5F85658Q37403909-30489E31-64A1-4155-B89D-DA828C26F88BQ37404470-DE40BD13-2D2E-4EA4-A2BF-3292FDD57D39Q37418102-F3F98070-9268-4857-96E3-E763F0F56AB6Q37706883-DBA565BE-CB89-4C9C-BCFC-C5A3EF5B09C0Q37846089-466D2922-CDE1-44E3-A5B5-1BA47FD1790FQ38709204-BF798732-840A-4C55-8322-8AFC323A05DCQ41692262-54179051-ABC7-4FFA-8004-309601352419Q41697318-E010B1D0-7658-4D04-AF4E-0BEEE1DFD784Q42283864-49B57850-235C-4D37-9E3A-101723069A76Q45083786-0DAE3AC1-A425-4404-A163-D5BEBB9151C5Q46027111-0FC69260-0D86-4492-98EE-A86D753729ABQ46076173-C1F07760-F307-4CA6-AB36-9F55F767E15BQ46499364-CB2B4CE5-0D79-4E8B-AEA6-A297425BEE06Q46620362-FD3F07A6-15FD-4FAE-99BF-D5D06A24C18AQ47321427-E60DE314-528C-42D5-A434-452BBE5E2989Q50970088-9E181EB3-E5E5-43F5-8A28-9D3CB13798FBQ51403034-C2397CBC-B87B-408F-973D-70AA09347E02
P2860
The dawn phenomenon revisited: implications for diabetes therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The dawn phenomenon revisited: implications for diabetes therapy.
@ast
The dawn phenomenon revisited: implications for diabetes therapy.
@en
type
label
The dawn phenomenon revisited: implications for diabetes therapy.
@ast
The dawn phenomenon revisited: implications for diabetes therapy.
@en
prefLabel
The dawn phenomenon revisited: implications for diabetes therapy.
@ast
The dawn phenomenon revisited: implications for diabetes therapy.
@en
P356
P1433
P1476
The dawn phenomenon revisited: implications for diabetes therapy.
@en
P2093
David S Schade
Mary F Carroll
P356
10.4158/EP.11.1.55
P577
2005-01-01T00:00:00Z